Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is a promising biotechnology company with a strong focus on precision medicine in the field of oncology. Their extensive capabilities in identifying and validating translational biomarkers, along with a pipeline of clinical and preclinical product candidates targeting key drivers of disease, make them well-positioned for success in the competitive market of targeted therapeutics. With positive clinical trial results and a potential for off-label use in HLA-A*02:01-positive patients, IDEAYA Biosciences has a strong outlook for future revenue growth. However, as with any biotech company, there are risks involved, such as R&D and regulatory setbacks, potential competition, and commercial challenges. Despite these risks, we believe that the company's solid foundation and potential for success make it a promising investment opportunity.

Bears say

IDEAYA Biosciences is a developmental-stage biotech company working to develop targeted therapies for select cancer patient populations. While the company's clinical stage product candidates show promise, with plans to submit multiple regulatory packages and interim analysis of OS data in the middle of 2027, the current market domination of competitors in the mUM space and risks associated with developmental pipelines lead to a negative outlook on their stock.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.